Abstract
Although multidrug resistance (MDR) proteins are known to play a role in drug resistance and modification pharmacodynamic characteristics of certain conventional chemotherapeutics, information about their interactions with tyrosine kinase inhibitors (TKIs) remains fragmentary and somewhat controversial. The chronic administration of TKIs in many clinical situations strongly suggests that any possible interactions with MDR transporters should be studied as a function of time. For example, short periods of exposure to TKIs could provide insights into the nature of the binding to MDR-related proteins, either as substrates or as inhibitors, whereas prolonged exposure to TKIs could provide insights into cellular responses to binding/inhibition of MDR-related proteins. In this report, we provide evidence that suggests that both Gefitinib and Vandetanib may act as transported substrates for Breast Cancer Resistance Protein (BCRP, ABCG2). Conversely, the interaction of Gefitinib and Vandetanib with P-glycoprotein (PgP, MDR1) appeared to be as inhibitors alone. Consistent with this, short periods of exposure (≤24 h) to either Gefitinib or Vandetanib increased the effectiveness of SN-38, the active metabolite of CPT-11. Conversely, prolonged exposure (5 days) decreased SN-38 effectiveness, and was associated with BCRP up-regulation and reduced cell accumulation in S-phase, possibly though reduced intracellular accumulation of SN-38. This report underlines the needs for more detailed characterisation new biologically targeted anticancer drugs, in particular analysing periods of both short and prolonged drug exposure reflecting potentially distinct situations in the clinic in order to optimise future development in combination with established chemotherapeutic approaches.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zhong H, Bowen JP (2007) Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 7:1379–1393
Press MF, Lenz HJ (2007) EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67:2045–2075
Ono M, Kuwano M (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12:7242–7251
Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A (2006) The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 1766:120–139
Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A (2004) Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells. Br J Cancer 91:1964–1969
Giannelli G, Azzariti A, Sgarra C, Porcelli L, Antonaci S, Paradiso A (2006) ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol 71:479–485
Giannelli G, Sgarra C, Porcelli L, Azzariti A, Antonaci S, Paradiso A (2008) EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett 262:257–264
Hoffmann S, Gläser S, Wunderlich A et al (2006) Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors–a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg 391:589–596
Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A (2008) Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 75:1035–1044
Leggas M, Panetta JC, Zhuang Y et al (2006) Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66:4802–4807
Azzariti A, Porcelli L, Xu JM, Simone GM, Paradiso A (2006) Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. World J Gastroenterol 12:5140–5147
Shi Z, Peng XX, Kim IW et al (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67:11012–11020
Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y (2004) Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3:1119–1125
Nakamura Y, Oka M, Soda H et al (2005) Gefitinib (“Iressa”, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65:1541–1546
Elkind NB, Szentpétery Z, Apáti A et al (2005) Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65:1770–1777
Lemos C, Jansen G, Peters GJ (2008) Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 98:857–862
Italiano A, Besse B, Planchard D, Soria JC (2007) Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives. Bull Cancer 94(7 Suppl):F177–F188
O’Connor R (2007) The pharmacology of cancer resistance. Anticancer Res 27:1267–1272
Gillet JP, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237–262
Azzariti A, Colabufo NA, Berardi F et al (2006) Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol Cancer Ther 5:1807–1816
Kitazaki T, Oka M, Nakamura Y et al (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49:337–343
Mi Y, Lou L (2007) ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer 97:934–940
Azzariti A, Xu JM, Porcelli L, Paradiso A (2004) The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol 68:135–144
Colabufo NA, Berardi F, Cantore M et al (2008) 4-Biphenyl and 2-naphthyl substituted 6, 7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem 16:3732–3743
Rautio J, Humphreys JE, Webster LO et al (2006) In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786–792
Kangas L, Grönroos M, Nieminem AL (1984) Bioluminescence of cellular ATP: a new method for evaluating agents in vitro. Med Biol 62:338–343
Taub ME, Podila L, Almeida I (2005) Functional assessment of multiple P-glycoprotein (P-gp) probe substrate: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 33:1679–1687
Colabufo NA, Berardi F, Cantore M et al (2008) Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem 16:362–373
Polli JW, Wring SA, Humphreys JE et al (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620–628
Wang X, Morris ME (2007) Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos 35:268–274
Wang Q, Strab R, Kardos P et al (2008) Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharm 356:12–18
Lopez JP, Wang-Rodriguez J, Chang C et al (2007) Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg 133:1022–1027
Nagashima S, Soda H, Oka M et al (2006) BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 58:594–600
Liu H, Cheng D, Weichel AK et al (2006) Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. Int J Oncol 29:1237–1246
Wedge SR, Ogilvie DJ, Dukes M et al (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645–4655
Wakeling AE, Guy SP, Woodburn JR et al (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749–5754
Usuda J, Ohira T, Suga Y et al (2007) Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a “never-smoked” female patient with advanced non-small cell lung cancer. Lung Cancer 58:296–299
Acknowledgments
We thank Dr. Andy Ryan (Astra Zeneca, Macclesfield, Cheshire, United Kingdom) for the helpful review of the manuscript. This study was supported by grants from the Italian Ministry of Health (Project of Integrated Program, 2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Azzariti, A., Porcelli, L., Simone, G.M. et al. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol 65, 335–346 (2010). https://doi.org/10.1007/s00280-009-1039-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1039-0